TITO R MENDOZA to Disease-Free Survival
This is a "connection" page, showing publications TITO R MENDOZA has written about Disease-Free Survival.
Connection Strength
0.046
-
A phase II study of dose-dense temozolomide and lapatinib for recurrent low-grade and anaplastic supratentorial, infratentorial, and spinal cord ependymoma. Neuro Oncol. 2021 03 25; 23(3):468-477.
Score: 0.021
-
Net clinical benefit analysis of radiation therapy oncology group 0525: a phase III trial comparing conventional adjuvant temozolomide with dose-intensive temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2013 Nov 10; 31(32):4076-84.
Score: 0.013
-
The symptom burden of cancer: Evidence for a core set of cancer-related and treatment-related symptoms from the Eastern Cooperative Oncology Group Symptom Outcomes and Practice Patterns study. Cancer. 2013 Dec 15; 119(24):4333-40.
Score: 0.012